2-氨基-1-(3-氟苯基)乙醇 | 402-96-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氨基-1-(3-氟苯基)乙醇
• 中文别名: ALPHA-羟基-间氟苯乙胺
• 英文名称: 2-hydroxy-2-(3-fluorophenyl)-ethanamine
• 英文别名: 2-(3-fluorophenyl)-2-hydroxyethanamine；2-amino-1-(3-fluorophenyl)ethanol；2-hydroxy-2-(3-fluorophenyl) ethanamine；2-hydroxy-2-(3-fluorophenyl)ethanamine
• CAS: 402-96-0
• 化学式: C₈H₁₀FNO
• mdl: MFCD09041574
• 分子量: 155.172
• InChiKey: KLIPUNKCUPNMHM-UHFFFAOYSA-N

物化性质

• 沸点：
  287.4±25.0 °C(Predicted)
• 密度：
  1.208±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2922199090

反应信息

• 作为反应物：
  描述：

  2-氨基-1-(3-氟苯基)乙醇 、 对甲氧基苯基丙酮 在 sodium borohydrid 作用下， 生成 N-[2-(4-methoxyphenyl)-1-methylethyl]-2-hydroxy-2-(3-fluorophenyl)ethanamine
  参考文献：
  名称：

  Secondary amines

  摘要：

  该公式（II）的化合物：##STR1##或其盐；其中R.sup.1为氢或甲基，R.sup.2为氢或甲基，R.sup.3为氢，C.sub.1-12直链或支链烷基，C.sub.3-10环烷基，苯基(C.sub.1-4)-烷基或苄基，可选择地被C.sub.1-4烷基，C.sub.1-4烷氧基或卤素取代；R.sup.4为氢，卤素，羟基，C.sub.1-4烷基或C.sub.1-4烷氧基，R.sup.5为氢或氟，R.sup.6为氢或氟，R.sup.7为卤素；n为1或2，具有抗肥胖和/或抗高血糖活性。

  公开号：

  US04622342A1
• 作为产物：
  描述：

  2-(3-fluorophenyl)-2-((trimethylsilyl)oxy)acetonitrile 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 生成 2-氨基-1-(3-氟苯基)乙醇
  参考文献：
  名称：

  1-Aryl-2-((6-aryl)pyrimidin-4-yl)amino)ethanols as competitive inhibitors of fatty acid amide hydrolase

  摘要：

  A series of 1-aryl-2-(((6-aryl)pyrimidin-4-yl)amino)ethanols have been found to be competitive inhibitors of fatty acid amide hydrolase (FAAH). One member of this class, JNJ-40413269, was found to have excellent pharmacokinetic properties, demonstrated robust central target engagement, and was efficacious in a rat model of neuropathic pain. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.01.064

文献信息

• [EN] NOVE PHENYL/PYRIDINE SERIES SUBSTITUED BY HYDROXYETHYLAMINO FOR THE TREATMENT OF CANCER<br/>[FR] NOUVELLE SÉRIE PHÉNYLE/PYRIDINE SUBSTITUÉE PAR HYDROXYÉTHYLAMINO POUR LE TRAITEMENT DU CANCER
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014106606A1

  公开（公告）日：2014-07-10

  The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7 and W are as described herein, compositions including the compounds and methods of using the compounds.

  本发明提供了具有通用公式(I)的新颖化合物，其中R1、R2、R3、R4、R5、R6、R7和W如本文所述，包括这些化合物的组合物以及使用这些化合物的方法。
• Thiazolinone unsubstituted quinolines
  申请人：Chen Li

  公开号：US20060004045A1

  公开（公告）日：2006-01-05

  Thiazolinone quinoline derivatives having no substitution on the quinoline ring active as CDK1 inhibitors which are useful as anti-proliferation agents such as for treating solid tumors.

  噻唑酮喹啉衍生物在喹啉环上没有取代基，作为CDK1抑制剂活性，可用作抗增殖剂，例如用于治疗实体肿瘤。
• Aromatic amino-alcohol derivatives having anti-diabetic and anti-obesity
  申请人：Sankyo Company, Limited

  公开号：US05576340A1

  公开（公告）日：1996-11-19

  Compounds of formula (I): ##STR1## (wherein: R.sup.0 is hydrogen, methyl or hydroxymethyl; R.sup.1 is substituted alkyl; R.sup.2 and R.sup.3 are each hydrogen, halogen, hydroxy, alkoxy, carboxy, alkoxycarbonyl, alkyl, nitro, haloalkyl, or substituted alkyl; X is oxygen or sulfur; and Ar optionally substituted phenyl or naphthyl); and pharmaceutically acceptable salts thereof have a variety of valuable pharmaceutical activities, including anti-diabetic and anti-obesity activities; in addition, they are capable of treating or preventing hyperlipemia and hyperglycemia and, by inhibiting the action of aldose reductase, they can also be effective in the treatment and prevention of complications of diabetes.

  化合物的化学式（I）：##STR1##（其中：R.sup.0为氢、甲基或羟甲基；R.sup.1为取代烷基；R.sup.2和R.sup.3分别为氢、卤素、羟基、烷氧基、羧基、烷氧羰基、烷基、硝基、卤代烷基或取代烷基；X为氧或硫；Ar为可选的取代苯基或萘基）；以及其药学上可接受的盐具有多种有价值的药理活性，包括抗糖尿病和抗肥胖活性；此外，它们能够治疗或预防高脂血症和高血糖，并通过抑制醛糖还原酶的作用，它们还可以有效地治疗和预防糖尿病并发症。
• Cinnamic acid derivatives, their preparation, and pharmaceutical
  申请人：Beecham Group Limited

  公开号：US04309443A1

  公开（公告）日：1982-01-05

  A compound of the formula (I): ##STR1## or a pharmaceutically acceptable ester, amide or salt thereof wherein R.sub.1 is a hydrogen, fluorine, chlorine or bromine atom or a hydroxyl, hydroxymethyl, methyl, methoxyl, amino, formamido, acetamido, methylsulphonylamido, nitro, benzyloxy, methylsulphonylmethyl, ureido, trifluoromethyl or p-methoxybenzylamino group; R.sub.2 is a hydrogen, fluorine, chlorine or bromine atom or a hydroxyl group; R.sub.3 is a hydrogen, chlorine or bromine atom or a hydroxyl group; R.sub.4 is a hydrogen, chlorine or fluorine atom or a methyl, methoxyl or hydroxyl group or a carboxylic acid group or a salt, ester or amide thereof; R.sub.5 is a hydrogen atom or a methyl group; R.sub.6 is a hydrogen atom or a methyl group; R.sub.7 is a hydrogen atom or a methyl or ethyl group; R.sub.8 is a hydrogen atom or a methyl or ethyl group; X is an oxygen atom or a bond, and Y is an alkylene group of up to 5 carbon atoms, or a bond has been found to possess anti-obesity and/or anti-hyperglycaemic activity.

  该化合物的结构式为（I）：##STR1##或其药学上可接受的酯、酰胺或盐，其中R.sub.1是氢、氟、氯或溴原子或羟基、羟甲基、甲基、甲氧基、氨基、甲酰胺基、乙酰胺基、甲基磺酰胺基、硝基、苄氧基、甲基磺基甲基、脲基、三氟甲基或对甲氧基苄氨基基团；R.sub.2是氢、氟、氯或溴原子或羟基；R.sub.3是氢、氯或溴原子或羟基；R.sub.4是氢、氯或氟原子或甲基、甲氧基或羟基或羧酸基或其盐、酯或酰胺；R.sub.5是氢原子或甲基基团；R.sub.6是氢原子或甲基基团；R.sub.7是氢原子或甲基或乙基基团；R.sub.8是氢原子或甲基或乙基基团；X是氧原子或键，Y是最多含有5个碳原子的烷基基团，或者发现具有抗肥胖和/或抗高血糖活性。
• SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS
  申请人：EISAI R&D MANAGEMENT CO., LTD.

  公开号：US20150105370A1

  公开（公告）日：2015-04-16

  Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.

  该公开的实施例涉及选择性替代喹啉化合物，其作为Toll样受体7和/或8的拮抗剂或抑制剂，并其在制药组合物中的使用，用于治疗系统性红斑狼疮（SLE）和狼疮性肾炎。